What's new and not so new on the antimicrobial horizon?

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Gram-positive infections: lessons learnt and novel solutions

Weight-based antibiotic dosing in a real-world European study of complicated skin and soft-tissue infections due to methicillin-resistant Staphylococcus.

New epidemiology of Staphylococcus aureus infection in Asia

G. Cornaglia, A. Lönnroth, M. Struelens

Gut bacterial microbiota and obesity

M.F.Q. Kluytmans-VandenBergh, J.A.J.W. Kluytmans

Molecular characterization of methicillin-resistant Staphylococcus aureus isolated over a 2-year period in a Qatari hospital from multinational patients

Control of multidrug-resistant Gram-negative bacteria in low- and middle-income countries—high impact interventions without much resources N. Singh,

European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years.

The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram- positive bacteria M.J. Rybak Clinical Microbiology and Infection

European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after.

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Clinical impact of antibiotic-resistant Gram-positive pathogens

Cost-effectiveness of universal MRSA screening on admission to surgery

European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after.

Antimicrobial drug use and infection control practices associated with the prevalence of methicillin-resistant Staphylococcus aureus in European hospitals

J.-P. Stahl Clinical Microbiology and Infection

Use of surveillance cultures and enteral vancomycin to control methicillin-resistant Staphylococcus aureus in a paediatric intensive care unit K. Thorburn,

Appropriate vs. inappropriate antimicrobial therapy

W. Witte, B. Pasemann, C. Cuny Clinical Microbiology and Infection

Targeted antibiotic management of ventilator-associated pneumonia

Vector control: a cornerstone in the malaria elimination campaign

Rapid genotyping of methicillin-resistant Staphylococcus aureus (MRSA) isolates using miniaturised oligonucleotide arrays S. Monecke, R. Ehricht Clinical.

L.R. Peterson Clinical Microbiology and Infection

Junior doctors' knowledge and perceptions of antibiotic resistance and prescribing: a survey in France and Scotland C. Pulcini, F. Williams, N. Molinari,

Spa typing directly from a mecA, spa and pvl multiplex PCR assay—a cost-effective improvement for methicillin-resistant Staphylococcus aureus surveillance

A new multiplex PCR for easy screening of methicillin-resistant Staphylococcus aureus SCCmec types I–V K. Boye, M.D. Bartels, I.S. Andersen, J.A. Møller,

Low prevalence of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in Belgian hospitals C. Nonhoff, O. Denis,

A variant of the Southern German clone of methicillin-resistant Staphylococcus aureus is predominant in Croatia A. Budimir, R.H. Deurenberg, Z. Bošnjak,

Bacterial resistance—the clinical challenge

Risk factors and mortality of healthcare-associated and community-acquired Staphylococcus aureus bacteraemia M. Bassetti, E.M. Trecarichi, A. Mesini,

Evaluation of three chromogenic media (MRSA-ID, MRSA-Select and CHROMagar MRSA) and ORSAB for surveillance cultures of methicillin-resistant Staphylococcus.

Strategies for managing today's infections

Clinical Microbiology and Infection

Population structure analyses of Staphylococcus aureus at Tygerberg Hospital, South Africa, reveals a diverse population, a high prevalence of Panton–Valentine.

Body site colonization in patients with community-associated methicillin-resistant Staphylococcus aureus and other types of S. aureus skin infections

M. Aires-de-Sousa Clinical Microbiology and Infection

Clinical profile of ceftobiprole, a novel β-lactam antibiotic

Characterisation of non-multiresistant methicillin-resistant Staphylococcus aureus (including EMRSA-15) in Kuwait Hospitals E.E. Udo, N. Al-Sweih, B.

A. Bryskier Clinical Microbiology and Infection

Y. Tveten, A. Jenkins, A.G. Allum, B.-E. Kristiansen

Antibacterial drug discovery in the 21st century

Can β-lactams be re-engineered to beat MRSA?

Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals G.L. Cartolano,

A.W. Karchmer Clinical Microbiology and Infection

P.M. Hawkey Clinical Microbiology and Infection

Increased incidence of methicillin-resistant Staphylococcus aureus ST80, novel ST125 and SCCmecIV in the south-eastern part of Norway during a 12-year.

Evolving problems with resistant pathogens

Community-associated Staphylococcus aureus infections and nasal carriage among children: molecular microbial data and clinical characteristics G. Sdougkos,

Sequential time to positivity of blood cultures can be a predictor of prognosis of patients with persistent Staphylococcus aureus bacteraemia M.-S. Hsu,

G.M. Rossolini, E. Mantengoli Clinical Microbiology and Infection

Clinical Microbiology and Infection

J.-M. Rolain, C. Abat, P. Brouqui, D. Raoult

Pan-European early switch/early discharge opportunities exist for hospitalized patients with methicillin-resistant Staphylococcus aureus complicated skin.

Rise and subsequent decline of community-associated methicillin resistant Staphylococcus aureus ST30-IVc in Copenhagen, Denmark through an effective search.

Panton–Valentine leukocidin-encoding bacteriophage and gene sequence variation in community-associated methicillin-resistant Staphylococcus aureus J.A.

Abstracts Clinical Microbiology and Infection

New oral cephalosporins in pediatric community-acquired infections

J. Wilson, S. Elgohari, D. M. Livermore, B. Cookson, A. Johnson, T

A. Manzur, F. Gudiol Clinical Microbiology and Infection

W. Witte Clinical Microbiology and Infection

B.A. Cunha Clinical Microbiology and Infection

J.L. Balcázar Clinical Microbiology and Infection

G.C. Schito Clinical Microbiology and Infection

D.A. Robinson, M.C. Enright Clinical Microbiology and Infection

Genetic diversity of community-associated methicillin-resistant Staphylococcus aureus in southern Stockholm, H. Fang, G. Hedin, G. Li, C.E.

J. Segreti Clinical Microbiology and Infection

The future of diagnostic bacteriology

Presentation transcript:

What's new and not so new on the antimicrobial horizon? G.L. French Clinical Microbiology and Infection Volume 14, Pages 19-29 (December 2008) DOI: 10.1111/j.1469-0691.2008.02124.x Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 1 Chemical structures of: ceftobiprole medocaril (formerly BAL5788; water-soluble prodrug for parenteral administration) and its microbiologically active compound, ceftobiprole (formerly BAL9141); doripenem (formerly S-4661), meropenem and imipenem; iclaprim (formerly AR-100); and trimethoprim. aAdapted from: Schmitt-Hoffmann et al. [18]. bAdapted from: Jones et al. [17]. cAdapted from: Merrem IV Prescribing Information. dAdapted from: Primaxin IV Prescribing Information. eAdapted from: Schneider et al. [19]. Clinical Microbiology and Infection 2008 14, 19-29DOI: (10.1111/j.1469-0691.2008.02124.x) Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 2 Study design of STudy of Resistant Staphyloccocus aureus in Skin and Skin structure infections (STRAUSS) I trial (ceftobiprole phase 3 registration study). cSSSI, complicated skin and skin structure infection. Adapted from: Noel et al. [24]. Clinical Microbiology and Infection 2008 14, 19-29DOI: (10.1111/j.1469-0691.2008.02124.x) Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 3 Results of STudy of Resistant Staphyloccocus aureus in Skin and Skin structure infections (STRAUSS) I trial (ceftobiprole phase 3 registration study), showing the distribution of pathogens overall, and according to genera and species. Adapted from: Amsler et al., 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2006. Clinical Microbiology and Infection 2008 14, 19-29DOI: (10.1111/j.1469-0691.2008.02124.x) Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 4 Study design of doripenem phase 3 registration study. IV, intravenous; PO, oral. Adapted from: Malafaia et al., 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2006, Presentation No. L-1564b. Clinical Microbiology and Infection 2008 14, 19-29DOI: (10.1111/j.1469-0691.2008.02124.x) Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 5 Study design of ASSIST I trial (iclaprim phase 3 registration study). cSSSI, complicated skin and skin structure infection; MRSA, methicillin-resistant Staphylococcus aureus; IV, intravenous; ITT, intention-to-treat. Adapted from: Arpida press release (http://www.arpida.ch/users/1/content/assist-1_results_en.pdf?way2go=379f5f1fe9512a9ea14a3cf340abb953) (accessed 23 April 2008). Clinical Microbiology and Infection 2008 14, 19-29DOI: (10.1111/j.1469-0691.2008.02124.x) Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions